CD30/TNFRSF8 Antibody (HRS-4) Summary
| Immunogen |
human CD30 cell surface antigen
|
| Specificity |
CD30 (HRS-4)
|
| Isotype |
IgG1
|
| Clonality |
Monoclonal
|
| Host |
Mouse
|
| Gene |
TNFRSF8
|
| Purity |
Protein A or G purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
||
| Positive Control |
|
Reactivity Notes
Cross reacts with Cynomolgus Monkey and Rhesus Monkey.
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
|
| Buffer |
PBS
|
| Preservative |
0.09% Sodium Azide
|
| Concentration |
0.2 mg/ml
|
| Purity |
Protein A or G purified
|
Alternate Names for CD30/TNFRSF8 Antibody (HRS-4)
- CD30 antigen
- CD30
- CD30KI-1
- CD30L receptor
- cytokine receptor CD30
- D1S166EKi-1
- Ki-1 antigen
- Lymphocyte activation antigen CD30
- TNFRSF8
- tumor necrosis factor receptor superfamily member 8
- tumor necrosis factor receptor superfamily, member 8
Background
CD30 is a type I transmembrane glycoprotein of the TNF receptor superfamily. CD30 was originally identified as a cell surface antigen of Hodgkins and Reed-Sternberg cells using monoclonal antibody Ki-1. The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkins disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkins and Reed-Sternberg cells, CD30 is also found in some non-Hodgkins lymphomas (including Burkitts lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and the IL4 receptor.